Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BR 76

Known as: BR-76 
 
National Institutes of Health

Related topics

Related topics

2 relations
BR 1376

Broader (1)

Ellipticines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Recovering the triple coincidence of non-pure positron emitters in preclinical PET.
Non-pure positron emitters, with their long half-lives, allow for the tracing of slow biochemical processes which cannot be… Expand
2011
2011
New Methods for Labeling RGD Peptides with Bromine-76
Direct bromination of the tyrosine residues of peptides and antibodies with bromine-76, to create probes for PET imaging, has… Expand
2002
2002
Pharmacological evaluation of a Br‐76 analog of epibatidine: A potent ligand for studying brain nicotinic acetylcholine receptors
[76Br]‐Norchlorobromoepibatidine ([76Br]BrPH) is a specific and high affinity radioligand for the nicotinic acetylcholine… Expand
2002
2002
Preparation of a bromine-76 labelled analogue of epibatidine: a potent ligand for nicotinic acetylcholine receptor studies.
Epibatidine analogues have been labelled with I-123 for single photon emission computed tomography and with short half-life… Expand
1998
1998
Preparation and evaluation of N-acylated anthracycline analogues for radiolabelling with I-124 and Br-76 - potential radiotracers for in vivo assessment of multidrug resistance
 
1993
1993
Br-76 Metabromobenzylguanidine - An Analog of Norepinephrine for Pet Investigation of Heart Adrenergic Reuptake System
 
1986
1986
The in vitro involvement of topoisomerase II in the activity of aza-ellipticine analogues is not correlated with drug activity on isolated nuclei.
Aza-ellipticines are DNA intercalative ellipticine analogues with antitumor activity that induce protein-linked DNA breaks in NIH… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE